Analyzing pathways involving amino acid transporters (e.g., SLC1A5) or enzymes (e.g., GLS) can guide the use of glutaminase inhibitors, such as CB-839, for glutamine-addicted breast cancer (Wicker et al., 2021). Here, SLC38A7 is linked to breast carcinoma.